TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32341237

Group type: EXPERIMENTAL
Intervention: Polaprezinc (150 mg/d) plus pantoprazole (40 mg/d)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Rebamipide (300 mg/d) plus pantoprazole (40 mg/d)
Number of subjects: 210
Study: 32312302

Group type: EXPERIMENTAL
Intervention: Routine care + e-device for recording step count (fit bit)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Routine care + daily motivational e-messages to maintain the log book
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Routine care + e-device for measuring step count (fit bit) + daily motivational e-messages
Number of subjects: 120

Group type: COMPARATOR
Intervention: Routine clinical care (Control group)
Number of subjects: 120
Study: 36378671

Group type: EXPERIMENTAL
Intervention: Aleglitazar (PPAR-α/γ agonist)
Number of subjects: 7226

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7226
Study: 32233350

Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (LSG)
Number of subjects: 22
Study: 36374352

Group type: EXPERIMENTAL
Intervention: 3D-printed titanium surgical guide
Number of subjects: 38

Group type: COMPARATOR
Intervention: Free-hand extractions
Number of subjects: 38
Study: 33718273

Group type: EXPERIMENTAL
Intervention: Ae. aegypti pools screened for arboviruses by RT‐PCR
Number of subjects: 769541

Group type: EXPERIMENTAL
Intervention: Cx. quinquefasciatus pools screened for arboviruses by RT‐PCR
Number of subjects: 769541
Study: 32432669

Group type: EXPERIMENTAL
Intervention: Trigger of stereotype threat (A): residents read abstracts reporting that women had worse laparoscopic skill performance than men.
Number of subjects: 131

Group type: COMPARATOR
Intervention: Protection against stereotype threat (B): residents read abstracts with no difference in performance.
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Pro‐male gender bias perception among men.
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Pro‐male gender bias perception among women.
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Stereotype threat activation response.
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Stereotype threat activation and FLS score among women.
Number of subjects: 131
Study: 36068298

Group type: EXPERIMENTAL
Intervention: Catecholamines (specific dosage and duration not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 34409800

Group type: EXPERIMENTAL
Intervention: Periodontal endoscope‐assisted subgingival scaling
Number of subjects: 13

Group type: COMPARATOR
Intervention: Traditional subgingival scaling (control group)
Number of subjects: 13
Study: 32645137

Group type: EXPERIMENTAL
Intervention: GDF‐15 levels in the highest quartile (≥358 pg/mL)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: GDF‐15 levels across quartiles
Number of subjects: 416

Group type: COMPARATOR
Intervention: GDF‐15 levels predicted by SNPs
Number of subjects: 416
Study: 33805883

Group type: EXPERIMENTAL
Intervention: β-Hydroxy-β-Methylbutyrate (7.5 g) and L-Arginine α-Ketoglutarate (10 g) supplementation
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 32315057

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid (5 mg in 100 mL saline solution)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo saline solution
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Intravenous zoledronic acid
Number of subjects: 223
Study: 35578356

Group type: EXPERIMENTAL
Intervention: TOWER intervention (patient-facing opioid management app, progress note template, PCP training)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: TOWER intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (standard care)
Number of subjects: 40
Study: 33707980

Group type: COMPARATOR
Intervention: music‐based training group (MBT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: mindfulness‐based mental training group (MBMT)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: control group (CG)
Number of subjects: 30
Study: 32369036

Group type: EXPERIMENTAL
Intervention: Virtual Reality Cognitive Behavioral Therapy (VR-CBT)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 116
Study: 35773175

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 500
Study: 33894169

Group type: EXPERIMENTAL
Intervention: Sevuparin (18 mg/kg per day)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (NaCl, 0.9% solution)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Sevuparin
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 34078482

Group type: EXPERIMENTAL
Intervention: Fe-biofortified pearl millet
Number of subjects: 130

Group type: COMPARATOR
Intervention: Conventional pearl millet
Number of subjects: 130
Study: 33738495

Group type: EXPERIMENTAL
Intervention: Cabazitaxel (25 mg/m2 IV Q3W, prednisone, G-CSF)
Number of subjects: 222
Study: 35930378

Group type: EXPERIMENTAL
Intervention: Action Planning
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Realistic Effort Action Planning (REAP)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Information
Number of subjects: 221
Study: 32356185

Group type: EXPERIMENTAL
Intervention: sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: sofosbuvir/simeprevir/daclatasvir + ribavirin
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (SOF/DCV-based therapy)
Number of subjects: 104
Study: 32115652

Group type: EXPERIMENTAL
Intervention: Attention Modification Program (AMP, n=20)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Attention Control Condition (ACC, n=20)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Passive Waiting Group (PW, n=23)
Number of subjects: 63
Study: 34236460

Group type: EXPERIMENTAL
Intervention: Refixation of the SSC-tendon
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-refixation of the SSC-tendon
Number of subjects: 50
Study: 34381155

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/24 h for 7 days
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Clarithromycin 500 mg/12 h for 7 days
Number of subjects: 305

Group type: COMPARATOR
Intervention: Standard care only
Number of subjects: 305
Study: 32412629

Group type: EXPERIMENTAL
Intervention: Responsive Parenting (RP) intervention
Number of subjects: 197

Group type: COMPARATOR
Intervention: Control
Number of subjects: 197
Study: 32238020

Group type: EXPERIMENTAL
Intervention: Hysterectomy with uterine manipulator (UM) guidance
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional hysterectomy (control group)
Number of subjects: 0
Study: 32026839

Group type: EXPERIMENTAL
Intervention: Pure ice (500g)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Wetted ice (500g of ice in 50ml of water)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Watered ice (500g of ice in 500ml of water)
Number of subjects: 16
Study: 35305111

Group type: EXPERIMENTAL
Intervention: Human fibrinogen concentrate (70 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Human fibrinogen concentrate
Number of subjects: 30
Study: 32684362

Group type: EXPERIMENTAL
Intervention: 3.2 g/day CLA
Number of subjects: 66

Group type: COMPARATOR
Intervention: 3.2 g/day placebo (sunflower oil)
Number of subjects: 66
Study: 36330564

Group type: EXPERIMENTAL
Intervention: Habitual and Healthy Nordic diets with Usual Sodium intake
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Habitual and Healthy Nordic diets with Reduced Sodium intake
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: High salt ingestion or changes in diet
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 106
Study: 34412750

Group type: EXPERIMENTAL
Intervention: Jiedu Limai decoction
Number of subjects: 100
Study: 33079968

Group type: EXPERIMENTAL
Intervention: Elastic net model for predicting overdose
Number of subjects: 5293880

Group type: COMPARATOR
Intervention: Simpler models (few predictors)
Number of subjects: 5293880

Group type: COMPARATOR
Intervention: Baseline predictors only
Number of subjects: 5293880
Study: 34794261

Group type: EXPERIMENTAL
Intervention: Hydrogel dressing+vaseline gauze
Number of subjects: 168

Group type: COMPARATOR
Intervention: Vaseline gauze only
Number of subjects: 168
Study: 32810194

Group type: EXPERIMENTAL
Intervention: BBOFT+ intervention
Number of subjects: 1995
Study: 35088760

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acustimulation (TEA) at acupuncture points LI4 and ST36, performed for one hour twice daily for one month.
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acustimulation (TEA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham‐TEA
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Both TEA and sham‐TEA
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: TEA
Number of subjects: 42
Study: 34608724

Group type: EXPERIMENTAL
Intervention: Low-impact profile (n=150; 57.9%)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: High-impact profile (n=88; 34.0%)
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Moderate-impact profile (n=21; 8.1%)
Number of subjects: 259
Study: 33359382

Group type: EXPERIMENTAL
Intervention: Group educational intervention
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Individual intervention
Number of subjects: 149

Group type: COMPARATOR
Intervention: Conventional intervention
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: All interventions
Number of subjects: 149
Study: 35858874

Group type: EXPERIMENTAL
Intervention: TDF-ART
Number of subjects: 3543

Group type: COMPARATOR
Intervention: ZDV-ART
Number of subjects: 3543

Group type: COMPARATOR
Intervention: ZDV Alone
Number of subjects: 3543
Study: 33782365

Group type: EXPERIMENTAL
Intervention: Early-start T&E regimen (2W interval adjustments)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Late-start T&E regimen (8W intervals until W48 then 2W interval adjustments)
Number of subjects: 271
Study: 32151992

Group type: EXPERIMENTAL
Intervention: Body positive captions on average images
Number of subjects: 384

Group type: EXPERIMENTAL
Intervention: Body positive captions on thin images
Number of subjects: 384

Group type: COMPARATOR
Intervention: Average images
Number of subjects: 384

Group type: COMPARATOR
Intervention: Thin images
Number of subjects: 384
Study: 33341402

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation (n = 87)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Normal sleep (n = 86)
Number of subjects: 173
Study: 32728650

Group type: EXPERIMENTAL
Intervention: Parent Handbook
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parent Handbook Plus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 35343321

Group type: COMPARATOR
Intervention: 0% gradient (0CON)
Number of subjects: 25

Group type: COMPARATOR
Intervention: 2% gradient (2CON)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 2% at isoefficiency speed (2IES)
Number of subjects: 25
Study: 33712920

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic and resistance group exercise sessions (3 times per week)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Gentle exercise program (1 time per week)
Number of subjects: 54
Study: 33106226

Group type: EXPERIMENTAL
Intervention: Digital Health Literacy Assessment (DHLA)
Number of subjects: 1588

Group type: EXPERIMENTAL
Intervention: Logistic regression analysis
Number of subjects: 1588
Study: 36056413

Group type: EXPERIMENTAL
Intervention: Opening the Conversation (OC) intervention
Number of subjects: 100

Group type: COMPARATOR
Intervention: Side by Side (active control)
Number of subjects: 100
Study: 32716114

Group type: EXPERIMENTAL
Intervention: tivantinib (120 mg bid)
Number of subjects: 195

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 195
Study: 36176963

Group type: EXPERIMENTAL
Intervention: Pharmacopuncture
Number of subjects: 98

Group type: COMPARATOR
Intervention: Conservative care
Number of subjects: 98
Study: 33689694

Group type: EXPERIMENTAL
Intervention: Pain coping skills training, arthritis education, and usual care
Number of subjects: 384
Study: 36078628

Group type: COMPARATOR
Intervention: Ultrasound (US) + Isometrics
Number of subjects: 60
Study: 33475735

Group type: EXPERIMENTAL
Intervention: Svo2-guided transfusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (standard transfusion)
Number of subjects: 100
Study: 33348621

Group type: EXPERIMENTAL
Intervention: Milk containing A2 β-casein only
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional milk
Number of subjects: 33
Study: 32063213

Group type: EXPERIMENTAL
Intervention: High-quality peritoneal dialysis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Urea clearance
Number of subjects: 0
Study: 32241299

Group type: EXPERIMENTAL
Intervention: Early, systematic integration of oncology and specialized palliative care in intervention hospitals.
Number of subjects: 680

Group type: COMPARATOR
Intervention: Conventional care in control hospitals.
Number of subjects: 680
Study: 36281667

Group type: EXPERIMENTAL
Intervention: Icapamespib 10 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Icapamespib 20 mg
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Icapamespib 30 mg
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Icapamespib 20 mg (multiple ascending dose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Icapamespib 30 mg (multiple ascending dose)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (multiple ascending dose)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Icapamespib 30 mg (bioavailability)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Icapamespib (oral solution)
Number of subjects: 48
Study: 33905405

Group type: EXPERIMENTAL
Intervention: Methadone (0.08 mg/kg)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Morphine (0.08 mg/kg)
Number of subjects: 86
Study: 32969202

Group type: EXPERIMENTAL
Intervention: Iberdomide 0.03 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Iberdomide 0.1 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Iberdomide 0.3 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Iberdomide 1 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Iberdomide 2 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Iberdomide 4 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Iberdomide 6 mg
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Iberdomide 0.3 mg once daily for 14 days
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Iberdomide 1 mg once daily for 28 days
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Iberdomide 0.3 mg once daily for 28 days
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Iberdomide 1 mg once daily for 7 days with a 7-day washout, then once daily for 7 more days
Number of subjects: 99
Study: 32093499

Group type: EXPERIMENTAL
Intervention: Accelerometer-based compact system
Number of subjects: 17

Group type: COMPARATOR
Intervention: Clinical rating scales (BARS, SAS, MDS‐UPDRS III)
Number of subjects: 17
Study: 37622634

Group type: EXPERIMENTAL
Intervention: Micronized raloxifene 45 mg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Conventional raloxifene 60 mg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 49
Study: 33873267

Group type: EXPERIMENTAL
Intervention: HPLF + ACT (5-min cycling every 30 min)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: WEST + ACT
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: PA breaks
Number of subjects: 24

Group type: COMPARATOR
Intervention: HPLF + SIT
Number of subjects: 24
Study: 32798787

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily for 12 weeks
Number of subjects: 190
Study: 35379307

Group type: EXPERIMENTAL
Intervention: Targeted consultant pharmacist intervention to deprescribe opioids and BZDs (n = 8 practices)
Number of subjects: 1962

Group type: COMPARATOR
Intervention: Usual care (n = 7 practices)
Number of subjects: 1962

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 1962
Study: 32674743

Group type: EXPERIMENTAL
Intervention: Higher intake of cruciferous vegetables (>44.6 g/d)
Number of subjects: 684

Group type: COMPARATOR
Intervention: Lower intake of cruciferous vegetables (<15.0 g/d)
Number of subjects: 684

Group type: COMPARATOR
Intervention: Total vegetable intake and other vegetable types
Number of subjects: 684
Study: 35167360

Group type: EXPERIMENTAL
Intervention: Immediate Loving Kindness Meditation (LKM) group
Number of subjects: 979

Group type: COMPARATOR
Intervention: Deferred LKM group (control)
Number of subjects: 979
Study: 35339350

Group type: EXPERIMENTAL
Intervention: rTMS 10Hz, 2400 pulses
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: rTMS 20Hz, 3600 pulses
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 20
Study: 33040562

Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 56

Group type: COMPARATOR
Intervention: Meropenem
Number of subjects: 56
Study: 32097124

Group type: EXPERIMENTAL
Intervention: Cell-associated HIV-1 RNA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plasma viral load (VL)
Number of subjects: 0
Study: 34288635

Group type: EXPERIMENTAL
Intervention: DFT015
Number of subjects: 282
Study: 34279747

Group type: EXPERIMENTAL
Intervention: 60 mg of pseudoephedrine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 34789230

Group type: EXPERIMENTAL
Intervention: Chlorine treatment of water reservoirs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo treatment of water reservoirs
Number of subjects: 0
Study: 35091204

Group type: EXPERIMENTAL
Intervention: Behavioral cough suppression therapy (BCST) plus 6 treatment sessions involving exposure to nebulized capsaicin in progressively larger concentrations (n = 8)
Number of subjects: 14

Group type: COMPARATOR
Intervention: BCST plus 6 sessions of exposure to a single subthreshold dose of capsaicin (sham; n = 6)
Number of subjects: 14
Study: 35587678

Group type: EXPERIMENTAL
Intervention: Customized group received individualized brackets combined with Insignia appliance
Number of subjects: 71

Group type: COMPARATOR
Intervention: Non-customized group received Damon Q self‐locking brackets
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Customized group
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study: 32208828

Group type: EXPERIMENTAL
Intervention: Typical symptoms in women
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atypical symptoms in women
Number of subjects: 0
Study: 35240703

Group type: EXPERIMENTAL
Intervention: Meditation group (daily use of a mindfulness‐focused meditation app)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Routine care group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Meditation group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Frequent meditation
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Meditation group (7 or more times)
Number of subjects: 60
Study: 35588706

Group type: EXPERIMENTAL
Intervention: Perspectives app-based cognitive behavioral therapy (CBT) for 12 weeks
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Perspectives app-based cognitive behavioral therapy (CBT)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 80
Study: 33769952

Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment for 3 years
Number of subjects: 43
Study: 32616017

Group type: EXPERIMENTAL
Intervention: Fascia closure technique with sutures placed 5 mm apart and 5 mm away from the fascia edge
Number of subjects: 274

Group type: COMPARATOR
Intervention: Traditional fascia closure technique with sutures placed 1 cm apart and at least 1 cm away from the fascia edge
Number of subjects: 274
Study: 36239675

Group type: EXPERIMENTAL
Intervention: OTT166 eyedrops (2.5% or 5%) administered BID for 28 days
Number of subjects: 44
Study: 35305995

Group type: EXPERIMENTAL
Intervention: C‐CARES (education+FIT)
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: C‐CARES Plus (C‐CARES+personalized coaching)
Number of subjects: 326
Study: 33342524

Group type: EXPERIMENTAL
Intervention: Packed Promise intervention (monthly food boxes with $38 food value and $15 check for fruits and vegetables)
Number of subjects: 4750

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4750
Study: 36445957

Group type: COMPARATOR
Intervention: Group Z250 (control)/micro‐hybrid composite (Filtek Z250, 3M ESPE)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group EST/low‐viscosity bulk‐fill resin composite (Estelite Bulk Fill Flow, Tokuyama Dental Corp) + micro‐hybrid composite
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group NOV/nanofiber‐reinforced low‐viscosity composite (NovaPro Flow, Nanova) + micro‐hybrid composite
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Group RIB/polyethylene fiber [Ribbond, Ribbond Inc] + micro‐hybrid composite
Number of subjects: 32
Study: 32693833

Group type: COMPARATOR
Intervention: Vehicle-control (SD-101 0%)
Number of subjects: 87
Study: 33661180

Group type: COMPARATOR
Intervention: Sham Electroconvulsive Therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Other Novel Therapies
Number of subjects: 0
Study: 33197917

Group type: EXPERIMENTAL
Intervention: Dietary self-monitoring
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Physical activity recommendations
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Liraglutide 3.0 mg
Number of subjects: 282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 282
Study: 34340161

Group type: EXPERIMENTAL
Intervention: Higher NACM symptomatology
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Higher arousal/reactivity
Number of subjects: 52
Study: 32448358

Group type: COMPARATOR
Intervention: Immediate cord clamping (Group A)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (Group B)
Number of subjects: 132
Study: 36060146

Group type: EXPERIMENTAL
Intervention: Modified Guizhi Shaoyao Zhimu Decoction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral allopurinol tablets, 100 mg, 2 times a day
Number of subjects: 100
Study: 32939850

Group type: EXPERIMENTAL
Intervention: Foley catheter
Number of subjects: 1142

Group type: COMPARATOR
Intervention: Prostaglandins
Number of subjects: 1142
Study: 32975441

Group type: EXPERIMENTAL
Intervention: 500 mg of cannabis with 6.7% delta-9-tetrahydrocannabinol (THC)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10